Lose 15 kilograms with one shot! Weight loss miracle drug company Nord earns 83.6 billion

Weight Loss Miracle Drug Company Releases Earnings Report, Q4 Net Profit Soars 62%

Novo Nordisk AS reported a full-year revenue of DKK 232.261 billion in 2023, a YoY increase of 31%; net profit was DKK 83.683 billion, a YoY increase of 51%.

The company's fourth-quarter revenue was DKK 65.863 billion, a YoY increase of 37%; net profit was DKK 21.963 billion, a YoY increase of 62%.

Previously, Novo Nordisk AS projected a full-year sales growth of 32% to 38% (earlier expectations were 27% to 33%) and an operating profit growth of 40% to 46% (earlier expectations were 31% to 37%). The actual growth rates were 31% and 37%, slightly lower than expected, mainly due to insufficient production capacity.

Novo Nordisk AS stated that it expects the supply-demand imbalance to continue and is investing in internal and external production capacity to increase short-term and long-term supply and expand its product line.

For more financial details, please refer to the annual report:

https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2024/novo-nordisk-annual-report-2023.pdf

Can Weight Loss Really Be Achieved Through Medication?

In the past two years, the popular weight loss miracle drug, semaglutide, has been making waves in social media circles and is basically sold out in China. Many people have resorted to purchasing it through agents or queuing up at hospitals to get the medication.

It is understood that this drug has remarkable weight loss effects, with many netizens claiming to have lost 15 kilograms with just one injection or 40 kilograms with two injections (the actual weight loss effect depends on the individual's initial weight).

Semaglutide (available as the subcutaneous injection Ozempic, the oral tablet Rybelsus for blood sugar control, and the weight loss product Wegovy) comes in two main forms: injection and oral. Currently, the injection version is the main one used in China.

Recently, there is good news. On January 27th, the oral form of semaglutide was approved for market launch in China, giving everyone a "taste" of it. It seems that weight loss can really be achieved through medication!

Since the approval of semaglutide injection in China, its sales have grown rapidly. According to Novo Nordisk AS's announcement, the revenue from Ozempic in the Chinese market reached DKK 3.813 billion, equivalent to approximately RMB 4.003 billion, in the first three quarters of 2023, a YoY increase of 160%. In the third quarter, the revenue was DKK 1.600 billion, equivalent to approximately RMB 1.680 billion.YoY growth of 167%, the fastest growth rate among regional markets.

Review of last quarter's earnings report

Semaglutide has also brought significant performance growth to Novo Nordisk AS.

According to Novo Nordisk AS's Q3 2023 report, its cumulative sales for the first three quarters reached DKK 166.398 billion, a YoY growth of 29%. Among them, the combined sales of three semaglutide products reached approximately DKK 100.2 billion (about USD 14.8 billion), accounting for over 60% of the company's total sales.

The company currently has a market value of USD 478.2 billion, even surpassing Denmark's GDP, thanks to a weight-loss drug, making it extremely wealthy.

Goldman Sachs analysts predict that by 2030, the annual sales of the global anti-obesity drug market could reach around USD 100 billion, while the initial estimate for annual sales in early 2023 was only USD 6 billion.

Based on the strong performance in the first three quarters, Novo Nordisk AS previously raised its full-year sales and operating profit expectations.

It is expected that full-year sales will grow by 32% to 38% (previously expected to be 27% to 33%), and operating profit will grow by 40% to 46% (previously expected to be 31% to 37%).

Novo Nordisk AS stated that this guidance reflects the sales growth expectations for its North American and international businesses, primarily driven by the sales growth of GLP-1-based diabetes and obesity treatment drugs.

On August 8th last year, Novo Nordisk AS surged by 17% due to the announcement that its weight-loss therapy semaglutide can reduce adverse cardiovascular events (including cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) by 20% in a trial targeting overweight or obese adults with cardiovascular disease. The company expects to submit applications for the expansion of semaglutide 2.4 mg's indications to regulatory agencies in the United States and the European Union in 2023.